News

The OSTORA tablets, which will be manufactured in QS Pharma’s Pennsylvania facility, will be used for product launch and commercial sale. This new agreement builds on the continuing

PXVX-0200 is a live attenuated vaccine against cholera, which was previously approved and marketed in six countries under the brand name Orochol. The company expects to begin Phase

Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the regulation of dopaminergic pathways in the brain. As per the agreement Heptares receives upfront option grant and

The transparent topical gel which contains Cepalin, the proprietary botanical extract derived from onions, is clinically shown to improve the texture, color, softness and overall appearance of scars.

In the fourth quarter of 2012, USV will launch Vibact IBS based on the probiotic formulation Probi Digestis. Probi’s capsules based on the Lactobacillus plantarum 299v strain, will

Galapagos is expected to start a comprehensive safety evaluation to advance the compound towards Phase I trials. In October 2007, Galapagos entered into an alliance agreement providing Janssen

The patent provides the company with exclusive rights to LOR-253 until 2026. The patent covers LOR-253 composition of matter and its use in the treatment of a wide

5-fC is formed by oxidation of 5-hydroxymethylcytosine through TET hydroxylase and has been demonstrated to be an intermediate of the DNA demethylation process. The detection of 5-fC in

The new technology will enable biologics that are given as aqueous injections to be reformulated into a biocompatible, non-aqueous suspensions. The suspensions can be directly injected without reconstitution